IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v7y2016i1d10.1038_ncomms12616.html
   My bibliography  Save this article

Neutralizing blood-borne polyphosphate in vivo provides safe thromboprotection

Author

Listed:
  • Linda Labberton

    (Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center Hamburg-Eppendorf
    Clinical Chemistry, L1:00, Karolinska Institutet and University Hospital)

  • Ellinor Kenne

    (Clinical Chemistry, L1:00, Karolinska Institutet and University Hospital)

  • Andy T. Long

    (Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center Hamburg-Eppendorf)

  • Katrin F. Nickel

    (Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center Hamburg-Eppendorf
    Clinical Chemistry, L1:00, Karolinska Institutet and University Hospital)

  • Antonio Di Gennaro

    (Clinical Chemistry, L1:00, Karolinska Institutet and University Hospital)

  • Rachel A. Rigg

    (Clinical Chemistry, L1:00, Karolinska Institutet and University Hospital
    School of Medicine, Oregon Health & Science University)

  • James S. Hernandez

    (Mayo Clinic in Arizona)

  • Lynn Butler

    (Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center Hamburg-Eppendorf
    Clinical Chemistry, L1:00, Karolinska Institutet and University Hospital)

  • Coen Maas

    (University Medical Center Utrecht)

  • Evi X. Stavrou

    (Louis Stokes Veterans Administration Hospital
    Case Western Reserve University)

  • Thomas Renné

    (Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center Hamburg-Eppendorf
    Clinical Chemistry, L1:00, Karolinska Institutet and University Hospital)

Abstract

Polyphosphate is an inorganic procoagulant polymer. Here we develop specific inhibitors of polyphosphate and show that this strategy confers thromboprotection in a factor XII-dependent manner. Recombinant Escherichia coli exopolyphosphatase (PPX) specifically degrades polyphosphate, while a PPX variant lacking domains 1 and 2 (PPX_Δ12) binds to the polymer without degrading it. Both PPX and PPX_Δ12 interfere with polyphosphate- but not tissue factor- or nucleic acid-driven thrombin formation. Targeting polyphosphate abolishes procoagulant platelet activity in a factor XII-dependent manner, reduces fibrin accumulation and impedes thrombus formation in blood under flow. PPX and PPX_Δ12 infusions in wild-type mice interfere with arterial thrombosis and protect animals from activated platelet-induced venous thromboembolism without increasing bleeding from injury sites. In contrast, targeting polyphosphate does not provide additional protection from thrombosis in factor XII-deficient animals. Our data provide a proof-of-concept approach for combating thrombotic diseases without increased bleeding risk, indicating that polyphosphate drives thrombosis via factor XII.

Suggested Citation

  • Linda Labberton & Ellinor Kenne & Andy T. Long & Katrin F. Nickel & Antonio Di Gennaro & Rachel A. Rigg & James S. Hernandez & Lynn Butler & Coen Maas & Evi X. Stavrou & Thomas Renné, 2016. "Neutralizing blood-borne polyphosphate in vivo provides safe thromboprotection," Nature Communications, Nature, vol. 7(1), pages 1-14, November.
    • Handle: RePEc:nat:natcom:v:7:y:2016:i:1:d:10.1038_ncomms12616
    DOI: 10.1038/ncomms12616
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/ncomms12616
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/ncomms12616?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Chanel C. La & Stephanie A. Smith & Sreeparna Vappala & Reheman Adili & Catherine E. Luke & Srinivas Abbina & Haiming D. Luo & Irina Chafeeva & Matthew Drayton & Louise A. Creagh & Maria Guadalupe Jar, 2023. "Smart thrombosis inhibitors without bleeding side effects via charge tunable ligand design," Nature Communications, Nature, vol. 14(1), pages 1-18, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:7:y:2016:i:1:d:10.1038_ncomms12616. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.